Cerecor Inc., a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device. The company is developing CERC-301, an orphan neurological indication for controlling neurologic adaptation; CERC-406 for the treatment of Parkinson's disease; CERC-425, an orally active small molecule; CERC-611, a drug candidate for the treatment of partial-onset seizures in epilepsy; and CERC-913, a protide nucleotide for the treatment of mitochondrial disorder. It also developing preclinical therapies CERC-801, CERC-802, and CERC-803 for the treatment of inherited metabolic disorders. The company was formerly known as Ceregen Corporation and changed its name to Cerecor Inc. in March 2011. Cerecor Inc. was founded in 2011 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone410-522-8707
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.33 million
Profitability
Miscellaneous
Employees64
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable
Cerecor (NASDAQ:CERC) Frequently Asked Questions
What is Cerecor's stock symbol?
Cerecor trades on the NASDAQ under the ticker symbol "CERC."
How were Cerecor's earnings last quarter?
Cerecor Inc (NASDAQ:CERC) released its quarterly earnings data on Thursday, November, 14th. The company reported ($0.07) earnings per share for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. The company earned $5.61 million during the quarter, compared to analysts' expectations of $5.15 million. Cerecor had a negative net margin of 113.66% and a negative return on equity of 121.32%. View Cerecor's Earnings History.
When is Cerecor's next earnings date?
What price target have analysts set for CERC?
4 brokers have issued twelve-month price targets for Cerecor's shares. Their forecasts range from $10.00 to $12.00. On average, they anticipate Cerecor's stock price to reach $10.75 in the next year. This suggests a possible upside of 193.7% from the stock's current price. View Analyst Price Targets for Cerecor.
What is the consensus analysts' recommendation for Cerecor?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cerecor in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cerecor.
What are Wall Street analysts saying about Cerecor stock?
Here are some recent quotes from research analysts about Cerecor stock:
- 1. Maxim Group analysts commented, "Cerecor reported positive Parkinson’s disease (PD)- related neurogenic orthostatic hypotension (nOH). Key takeaways from the data include demonstration of a rapid and sustained improvement in systolic blood pressure upon standing particularly in the highest dose group (20mg); >7mmHg with max improvement of 29.1mmHg." (7/2/2019)
- 2. LADENBURG THALM/SH SH analysts commented, "We reiterate our Buy rating and $8 PT. Full data set is consistent with interim data." (7/2/2019)
- 3. HC Wainwright analysts commented, "We value Cerecor based on a discounted cash flow (DCF) approach that ascribes a total value of $530M to the company’s marketed product portfolio, neurology-focused assets and ultra-rare early-stage product candidate pipeline." (5/28/2019)
Has Cerecor been receiving favorable news coverage?
Press coverage about CERC stock has been trending neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cerecor earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 9.0 out of 10, indicating that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Cerecor.
Are investors shorting Cerecor?
Cerecor saw a decrease in short interest during the month of January. As of January 31st, there was short interest totalling 513,500 shares, a decrease of 7.4% from the January 15th total of 554,300 shares. Based on an average daily trading volume, of 90,600 shares, the days-to-cover ratio is currently 5.7 days. Approximately 1.4% of the shares of the company are short sold. View Cerecor's Current Options Chain.
Who are some of Cerecor's key competitors?
Some companies that are related to Cerecor include ImmunoGen (IMGN), Dova Pharmaceuticals (DOVA), Rhythm Pharmaceuticals (RYTM), Collegium Pharmaceutical (COLL), Arcus Biosciences (RCUS), Endonovo Therapeutics (ENDV), CannTrust (CNTTF), Homology Medicines (FIXX), ANI Pharmaceuticals (ANIP), Retrophin (RTRX), Aprea Therapeutics (APRE), DiaMedica Therapeutics (DMCAF), Frequency Therapeutics (FREQ), Provention Bio (PRVB) and Eagle Pharmaceuticals (EGRX).
What other stocks do shareholders of Cerecor own?
Who are Cerecor's key executives?
Cerecor's management team includes the folowing people:
- Ms. Mariam E. Morris, Consultant (Age 51)
- Dr. Simon C. Pedder Ph.D., Exec. Chairman (Age 58)
- Mr. Joseph M. Miller CPA, Chief Financial Officer (Age 45)
- Dr. Solomon H. Snyder, Founder and Chairman of Scientific Advisory Board (Age 80)
- Dr. Barbara S. Slusher, Founder and Member of Scientific Advisory Board (Age 54)
Who are Cerecor's major shareholders?
Cerecor's stock is owned by many different of retail and institutional investors. Top institutional investors include Ikarian Capital LLC (1.18%), State Street Corp (0.89%), Charles Schwab Investment Management Inc. (0.11%), UBS Group AG (0.06%), Spark Investment Management LLC (0.05%) and Barclays PLC (0.04%). Company insiders that own Cerecor stock include Armistice Capital Master Fund, Armistice Capital, Llc, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Pericles Calias, Peter Greenleaf and Simon Pedder. View Institutional Ownership Trends for Cerecor.
Which major investors are selling Cerecor stock?
Which major investors are buying Cerecor stock?
CERC stock was purchased by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, State Street Corp, UBS Group AG, Barclays PLC and Charles Schwab Investment Management Inc.. Company insiders that have bought Cerecor stock in the last two years include Armistice Capital Master Fund, Armistice Capital, Llc, James Archie Harrell Jr, Joseph M Miller, Matthew V Phillips, Pericles Calias, Peter Greenleaf and Simon Pedder. View Insider Buying and Selling for Cerecor.
How do I buy shares of Cerecor?
Shares of CERC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Cerecor's stock price today?
One share of CERC stock can currently be purchased for approximately $3.66.
How big of a company is Cerecor?
What is Cerecor's official website?
How can I contact Cerecor?
Cerecor's mailing address is 540 Gaither Road Suite 400, Rockville MD, 20850. The company can be reached via phone at 410-522-8707 or via email at [email protected]
MarketBeat Community Rating for Cerecor (NASDAQ CERC)
MarketBeat's community ratings are surveys of what our community members think about Cerecor and other stocks. Vote "Outperform" if you believe CERC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CERC will underperform the S&P 500 over the long term. You may vote once every thirty days.
